Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2008 | 03-2008 | 12-2007 | 09-2007 | 06-2007 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 250,536 | 196,281 | 105,157 | 200,547 | 84,464 |
| Marketable Securities | 290,787 | 247,592 | 284,791 | 267,831 | 110,304 |
| Receivables | 5,126 | 9,680 | 5,031 | 5,129 | 5,615 |
| TOTAL | $550,631 | $455,475 | $397,905 | $477,632 | $201,958 |
| Non-Current Assets | |||||
| PPE Net | 18,853 | 15,875 | 13,810 | 10,434 | 12,965 |
| Investments And Advances | 6,412 | 7,684 | 74,783 | 9,901 | 0 |
| Intangibles | 882 | 925 | 968 | 1,610 | 1,737 |
| Other Non-Current Assets | 3,268 | 6,297 | 6,325 | 5,514 | 2,998 |
| TOTAL | $29,415 | $30,781 | $95,886 | $27,459 | $17,700 |
| Total Assets | $580,046 | $486,256 | $493,791 | $505,091 | $219,658 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,240 | 9,084 | 3,826 | 7,057 | 5,669 |
| Accrued Expenses | 9,497 | 9,666 | 11,724 | 11,746 | 9,980 |
| TOTAL | $105,727 | $84,910 | $83,478 | $87,456 | $27,106 |
| Non-Current Liabilities | |||||
| Long Term Debt | 938 | 1,955 | 2,963 | 3,946 | 4,906 |
| Deferred Revenues | 80,806 | 58,822 | 60,636 | 61,652 | 7,840 |
| Other Non-Current Liabilities | 270 | 286 | 302 | 583 | 0 |
| TOTAL | $275,150 | $198,534 | $211,145 | $224,700 | $13,282 |
| Total Liabilities | $380,877 | $283,444 | $294,623 | $312,156 | $40,388 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,202 | 40,838 | 40,802 | 40,700 | 37,695 |
| Common Shares | 411 | 408 | 408 | 406 | 376 |
| Retained earnings | -239,992 | -227,232 | -225,993 | -227,655 | -174,863 |
| Other shareholders' equity | -1,660 | 646 | 300 | 145 | 536 |
| TOTAL | $199,169 | $202,812 | $199,168 | $192,935 | $179,270 |
| Total Liabilities And Equity | $580,046 | $486,256 | $493,791 | $505,091 | $219,658 |